Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial

Moderately hypofractionated radiotherapy is increasingly replacing conventional schedules (2 Gy/fraction) in adjuvant breast cancer treatment. Tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic biomarker, particularly in aggressive subtypes, but their role in node-negative patients and their relation to radiotherapy fractionation remain unclear. Immune infiltration in primary tumors was examined in the randomized Danish Breast Cancer Group HYPO trial, including 1329 node-negative breast cancer patients treated with breast-conserving surgery and randomized to standard fractionated (50 Gy/25 fractions) versus hypofractionated (40 Gy/15 fractions) radiotherapy. A case-cohort design included 349/1329 patients for histopathological analyses of TILs and immune cell subsets (CD8, CD4, FOXP3, CD68, CD11c). Associations with the primary endpoint, overall mortality (OM), were evaluated using multivariable flexible parametric survival models. Predictive effects of immune markers on fractionation were assessed through interaction tests. Median follow-up was 7.9 years. High TILs (cut-off ≥ 30%) were observed in 18% of tumors and showed a trend toward improved outcomes, most pronounced in patients with estrogen receptor (ER)-negative tumors (hazard ratio (HR) 0.43, 95% CI (0.09–2.03)). For ER-negative tumors, high CD8 + T-cell infiltration corresponded to an estimated absolute reduction in OM-risk of 43% compared with low CD8 + T-cell infiltration (HR 0.06 (0.01–0.47), test for interaction p = 0.13). In contrast, no consistent prognostic effect was observed in ER-positive disease. No predictive interaction was identified between immune markers and fractionation. Immune infiltration showed trends consistent with a prognostic association in node-negative breast cancer, with the strongest association in ER-negative tumors, in line with findings in node-positive cohorts. No predictive value of immune markers for fractionation was observed. These exploratory findings suggest that immune composition may hold prognostic information across risk groups.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-03-13
DOI
https://doi.org/10.1186/s12885-026-15859-w
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial

T Tramm, J. Alsner, Jens Overgaard, Marie Louise Holm Milo et al.
BMC Cancer
Cancer Immunotherapy and Biomarkers
article

Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial

T Tramm, J. Alsner, Jens Overgaard, Marie Louise Holm Milo, Mette Holck Nielsen, Patricia Switten Nielsen, Else Maae, Birgitte Vrou Offersen, Demet Özcan
article en

Abstract

Moderately hypofractionated radiotherapy is increasingly replacing conventional schedules (2 Gy/fraction) in adjuvant breast cancer treatment. Tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic biomarker, particularly in aggressive subtypes, but their role in node-negative patients and their relation to radiotherapy fractionation remain unclear. Immune infiltration in primary tumors was examined in the randomized Danish Breast Cancer Group HYPO trial, including 1329 node-negative breast cancer patients treated with breast-conserving surgery and randomized to standard fractionated (50 Gy/25 fractions) versus hypofractionated (40 Gy/15 fractions) radiotherapy. A case-cohort design included 349/1329 patients for histopathological analyses of TILs and immune cell subsets (CD8, CD4, FOXP3, CD68, CD11c). Associations with the primary endpoint, overall mortality (OM), were evaluated using multivariable flexible parametric survival models. Predictive effects of immune markers on fractionation were assessed through interaction tests. Median follow-up was 7.9 years. High TILs (cut-off ≥ 30%) were observed in 18% of tumors and showed a trend toward improved outcomes, most pronounced in patients with estrogen receptor (ER)-negative tumors (hazard ratio (HR) 0.43, 95% CI (0.09–2.03)). For ER-negative tumors, high CD8 + T-cell infiltration corresponded to an estimated absolute reduction in OM-risk of 43% compared with low CD8 + T-cell infiltration (HR 0.06 (0.01–0.47), test for interaction p = 0.13). In contrast, no consistent prognostic effect was observed in ER-positive disease. No predictive interaction was identified between immune markers and fractionation. Immune infiltration showed trends consistent with a prognostic association in node-negative breast cancer, with the strongest association in ER-negative tumors, in line with findings in node-positive cohorts. No predictive value of immune markers for fractionation was observed. These exploratory findings suggest that immune composition may hold prognostic information across risk groups.

BMC Cancer
Aarhus University (DK), Aalborg University Hospital (DK), Odense University Hospital (DK), Aarhus University Hospital (DK), Vejle Sygehus (DK), Aalborg University (DK)
Good health and well-being
Openalex Percentile: Top 23%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.